A company creator who has played a major role in founding and launching multiple high-performing companies with backing from ARCH Venture Partners.
Kristina Burow is currently a managing director at ARCH Venture Partners. Since joining ARCH in 2002, she has played a significant role in the creation and development of a number of companies. Kristina is a director of Gossamer Bio (Nasdaq: GOSS), Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Metacrine, Scholar Rock (Nasdaq: SRRK), Unity Biotechnology (Nasdaq: UBX), Beam Therapeutics (NASDAQ: BEAM), Boundless Bio, Autobahn Therapeutics, AgBiome and Vir Biotechnology (Nasdaq: VIR). She previously was a co-founder and director of Receptos, which was acquired by Celgene. Kristina has participated in a number of other ARCH portfolio companies including Mindstrong, Kura Oncology (Nasdaq: KURA), Kythera Biopharmaceuticals (acquired by Allergan) and Ikaria (acquired by Mallinckrodt) and was a co-founder and board member of Sapphire Energy. Prior to joining ARCH, she was an associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation, Kristina directed chemistry operations and was active in business development, helping to create numerous companies as spin-outs from GNF. She holds an MBA from the University of Chicago, an M.A. in chemistry from Columbia University and a B.S. in chemistry from the University of California, Berkeley. While at Berkeley she was a member of the Division 1 swim team.